National Oilwell Varco
NOV
$18.76
-2.65%
NOV Inc. designs, manufactures, and sells a broad portfolio of equipment and components for the oil and gas industry, including rig equipment, downhole tools, drill pipe, and well casing, organized into two reportable segments: energy products and services and energy equipment. The company is a scaled, globally diversified supplier to integrated majors, national oil companies, independents, and drilling contractors, with international markets contributing nearly two-thirds of annual revenue, giving it a distinct position as a capital-goods bellwether for global drilling activity rather than a pure-play commodity producer. The current investor narrative is a tug-of-war between improving capital-returns discipline — underscored by a 20% increase in the regular quarterly dividend announced in February 2026 and a $876 million trailing-twelve-month free cash flow base — and a soft North American demand backdrop, with the most recent quarter (Q4 2025) posting a $78 million net loss and revenue down 1.3% year over year. Bulls point to international and offshore activity, backlog conversion, and cost actions as the path to margin recovery, while bears highlight the earnings miss, negative GAAP profitability, and a payout ratio above 100% as evidence that the cycle recovery is uneven.…
NOV
National Oilwell Varco
$18.76
Related headlines
People also watch
SLB
SLB
Baker Hughes
BKR
Halliburton
HAL
Archrock Inc
AROC
Kodiak Gas Services, Inc.
KGS
Investment Opinion: Should I buy NOV Today?
The synthesized recommendation is Hold. The core thesis is that NOV offers deep value on sales and book with a 15% free cash flow yield, but the earnings recovery embedded in the 15.68x forward PE and the $22.24 average analyst target (10.8% upside) has not yet appeared in reported results, and the consensus 'buy' rating (mean 2.5) masks a cautious distribution that includes a Goldman Sachs Sell. Until revenue and margins inflect, the risk/reward is balanced rather than compelling.
Supporting evidence for the Hold: the stock trades at 0.66x sales and 0.93x book, near the bottom of its multi-year range versus historical PS of 2.13x-2.76x in 2025 and 3.0x-4.9x in 2022-2023; trailing FCF of $876 million yields roughly 15% against a $5.81 billion market cap; the balance sheet is solid with debt-to-equity of 0.37 and a current ratio of 2.42; and the dividend yield of 3.27% was recently raised 20%. However, revenue declined 1.34% year over year in Q4 2025, gross margin fell to 20.29%, and the payout ratio of 131% exceeds earnings, so the value case depends on a recovery that is not yet visible in the numbers.
The biggest risks that could invalidate the thesis are a continued North American activity decline, a stall in the international/offshore capex recovery, and further margin compression that keeps GAAP earnings near zero. This Hold would upgrade to Buy if revenue growth turns positive and gross margin recovers above 21%, or if the stock pulls back toward the $17.00 analyst low target; it would downgrade to Sell if revenue declines accelerate, gross margin falls below 20%, or the dividend coverage deteriorates further. On balance, the stock is undervalued relative to its own history but fairly valued relative to its depressed current earnings, making it a value opportunity contingent on execution rather than a clear bargain.
Sign up to view all
NOV 12-Month Price Forecast
NOV presents a classic cyclical value setup: deeply discounted on sales (0.66x) and book (0.93x) with a 15% free cash flow yield, but with GAAP earnings near zero and revenue still contracting. The bull case depends on an international/offshore capex recovery that would lift EPS toward the consensus $1.92 and justify the 15.68x forward PE, while the bear case points to margin compression, a 131% payout ratio, and a wide analyst target range that reflects genuine disagreement. The stock's 54.74% one-year gain and 22.30% year-to-date advance show momentum leadership, but the 6-month relative underperformance of nearly 10 percentage points versus SPY suggests the market is waiting for fundamental confirmation. I would upgrade to bullish if revenue growth turns positive and gross margin recovers above 21%, and downgrade to bearish if revenue declines accelerate or the dividend coverage deteriorates further. With a 0.944 beta and a 7.73 short ratio, positioning is not crowded, so a positive catalyst could drive an outsized move toward the upper end of the target range.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on National Oilwell Varco's 12-month outlook, with a consensus price target around $22.08 and implied upside of +17.7% versus the current price.
Average Target
$22.08
0 analysts
Implied Upside
+17.7%
vs. current price
Analyst Count
—
covering this stock
Price Range
$17 - $26
Analyst target range
Nineteen analysts cover NOV, and the consensus recommendation is "buy" with a recommendation mean of 2.5 (where lower is more bullish), though the distribution skews cautious — recent actions include Goldman Sachs maintaining a Sell, Citigroup, BMO, and Piper Sandler at Neutral/Market Perform, and Barclays at Equal Weight after upgrading from Underweight in February 2026. The average target price of $22.24 implies roughly 10.8% upside from the current $20.07, a modest but positive expected return that leans mildly bullish rather than enthusiastically so. Consensus 2026 EPS of $1.92 and revenue of $10.06 billion underpin that target, implying analysts expect both an earnings rebound from the near-zero trailing base and a return to top-line growth. The target range spans $17.00 to $26.00, a spread of $9.00, or roughly 45% of the current price — a wide dispersion that signals genuine disagreement about the pace of the cycle recovery. The high target of $26.00 (about 30% above the current price) likely assumes multiple expansion on a successful international/offshore upcycle, margin recovery toward the 2024 gross-margin levels above 21%, and continued strong free cash flow funding dividends and buybacks. The low target of $17.00 (about 15% below current) prices in margin compression, further North American activity declines, and the risk that the earnings recovery stalls, leaving the stock expensive on cash-flow-adjusted metrics. The wide spread, combined with the mix of Buy and Sell ratings from major firms, indicates high uncertainty and limited conviction; the stock's 7.73 short ratio and 0.944 beta suggest that positioning is not crowded, so a positive catalyst — such as an earnings beat or an international order announcement — could drive an outsized move toward the upper end of the target range.
Drowning in data?
Find the real signal!
Bulls vs Bears: NOV Investment Factors
The bear case currently has stronger near-term evidence: revenue is contracting, GAAP earnings turned negative in Q4 2025, gross margins are compressing, and the dividend exceeds earnings. The bull case rests on a forward-looking recovery — a 15.68x forward PE, a 15% FCF yield, a 0.93x price-to-book, and analyst targets implying 10.8% upside — that has not yet appeared in reported results. The single most important tension is whether the consensus 2026 EPS of $1.92 and revenue of $10.06 billion materialize; if they do, the stock is deeply undervalued, but if the international/offshore capex recovery stalls, the current price embeds an earnings rebound that may not arrive. Momentum and relative strength favor the bulls, but the fundamental inflection remains unproven.
Bullish
- Deep value on sales and book: NOV trades at just 0.66x trailing sales and 0.93x book value, versus historical PS readings of 2.13x-2.76x in 2025 and 3.0x-4.9x in 2022-2023. The PB ratio is below the 1.0x-1.6x range seen from 2021 through 2024, placing the stock near the bottom of its multi-year valuation band, which historically has coincided with cyclical troughs.
- Robust free cash flow generation: Trailing-twelve-month free cash flow of $876 million against a $5.81 billion market cap implies an FCF yield of roughly 15%. Q4 2025 alone generated $472 million of FCF ($573 million operating cash flow less $101 million capex), and cash on hand rose to $1.552 billion from $1.207 billion sequentially.
- Strong balance sheet and liquidity: Debt-to-equity of 0.37 and a current ratio of 2.42 signal a conservatively financed balance sheet with ample liquidity. This provides resilience through the downcycle and capacity to fund the dividend and buybacks without stressing the capital structure.
- Analyst consensus sees upside: Nineteen analysts carry a consensus 'buy' rating (recommendation mean 2.5) with an average target price of $22.24, implying roughly 10.8% upside from $20.07. The high target of $26.00 implies about 30% upside and assumes a successful international/offshore upcycle and margin recovery.
Bearish
- Revenue stagnation and earnings miss: Q4 2025 revenue of $2.277 billion declined 1.34% year over year, and full-year 2025 revenue of roughly $8.74 billion contracted from approximately $8.87 billion in 2024. The quarterly cadence through 2025 ($2.103B, $2.188B, $2.176B, $2.277B) shows no meaningful top-line expansion, leaving the 2026 consensus revenue estimate of $10.06 billion dependent on an unproven inflection.
- GAAP profitability has collapsed: Q4 2025 produced a net loss of $78 million (EPS -$0.21) versus net income of $160 million (EPS $0.41) in Q4 2024, driven partly by a $147 million tax expense against just $66 million of pretax income. Trailing EPS of $0.025 and a net margin of 1.66% underscore how little GAAP profit is being generated relative to the $5.8 billion market cap.
- Margin compression across the board: Q4 2025 gross margin of 20.29% fell from 21.36% a year earlier, and the full-year gross margin of roughly 20.2% sits below the 21-22% range posted through much of 2024. Operating margin of 6.45% and ROE of 2.31% are weak for an industrial equipment supplier and reflect pricing and mix pressure.
- Dividend not covered by earnings: The dividend payout ratio of 131% means the distribution is not covered by GAAP earnings, sustainable only because of the strong cash flow. While the 20% dividend increase announced in February 2026 signals management confidence, a prolonged earnings downturn could force a reassessment of the payout.
NOV Technical Analysis
NOV is in a sustained recovery uptrend, with the shares up 54.74% over the past year versus a 15.01% gain for SPY, a relative-strength advantage of 39.73 percentage points. At $20.07, the stock sits at roughly 79.8% of its 52-week range of $12.29 to $21.93, positioning it in the upper portion of the band but still about 8.5% below the high — a profile that suggests momentum leadership rather than an overextended blow-off top. The 22.30% year-to-date gain confirms the trend has persisted through 2026, though the failure to reclaim the $21.93 high on multiple attempts signals that supply remains overhead. Recent momentum has cooled: the stock is down 3.00% over the past month and 2.24% on the latest session, underperforming SPY's -0.96% one-month return by 2.04 percentage points. That one-month softness conflicts with the strong 3-month (+7.56%) and 1-year (+54.74%) trends, a divergence that looks more like a consolidation/pullback within an uptrend than a reversal, especially since the 6-month gain of 7.44% still trails SPY's 17.44% — meaning the stock has been range-bound since spring after its explosive prior-year move. The short ratio of 7.73 days-to-cover indicates a meaningful short base that could fuel squeezes on upside catalysts, while the 0.944 beta implies the stock is slightly less volatile than the market, supporting moderate position sizing rather than aggressive risk-taking. Key resistance sits at the 52-week high of $21.93; a decisive breakout above that level would confirm trend continuation and likely draw momentum capital, while support rests at the 52-week low of $12.29, with intermediate support around the $18.00-$18.50 zone where the stock consolidated in June-July 2026. The maximum drawdown of -17.06% over the period shows the stock can correct sharply within its uptrend, so traders should respect the $18 area as the line that separates a healthy pullback from a trend break.
Beta
0.98
0.98x market volatility
Max Drawdown
-17.1%
Largest decline past year
52-Week Range
$14-$22
Price range past year
Annual Return
+41.1%
Cumulative gain past year
| Period | NOV Return | S&P 500 |
|---|---|---|
| 1m | -7.0% | -1.2% |
| 3m | -9.6% | +3.4% |
| 6m | -8.5% | +7.0% |
| 1y | +41.1% | +14.4% |
| ytd | +14.3% | +12.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
NOV Fundamental Analysis
Revenue is stagnating rather than growing: Q4 2025 revenue of $2.277 billion declined 1.34% year over year from $2.308 billion, and the sequential trend across 2025 was flat-to-lower — $2.103 billion in Q1, $2.188 billion in Q2, $2.176 billion in Q3, and $2.277 billion in Q4 — a pattern of no meaningful top-line expansion. Full-year 2025 revenue of roughly $8.74 billion compares to approximately $8.87 billion in 2024, confirming a modest contraction, and the lone disclosed segment datapoint (a $19 million royalty line) is too small to offset the core equipment softness. With consensus 2026 revenue estimated at $10.06 billion, the market is implicitly assuming a return to growth, but the recent quarterly cadence does not yet show that inflection, leaving the investment case dependent on an international/offshore capex recovery. Profitability is thin and deteriorating at the GAAP line: Q4 2025 produced a net loss of $78 million (EPS -$0.21) versus net income of $160 million (EPS $0.41) in Q4 2024, a dramatic swing driven partly by a $147 million tax expense against just $66 million of pretax income. Gross margin was 20.29% in Q4 2025, down from 21.36% a year earlier, and the full-year gross margin of roughly 20.2% sits below the 21-22% range the company posted through much of 2024, indicating pricing and mix pressure. Operating margin of 6.45% and net margin of just 1.66% are modest for an industrial equipment supplier, and the trailing EPS of $0.025 underscores how little GAAP profit is being generated relative to the $5.8 billion market cap. The balance sheet is the strongest part of the story: debt-to-equity of 0.37 and a current ratio of 2.42 signal solid liquidity, while trailing free cash flow of $876 million against a $5.81 billion market cap implies a robust FCF yield of roughly 15%. Q4 2025 operating cash flow of $573 million less $101 million of capex generated $472 million of free cash flow, and cash on hand rose to $1.552 billion from $1.207 billion sequentially, demonstrating genuine internal cash generation. However, ROE of 2.31% and ROA of 3.45% are weak, and the dividend payout ratio of 131% means the distribution is not currently covered by GAAP earnings — sustainable only because of the strong cash flow, which is the key metric to monitor.
Quarterly Revenue
$2.1B
2026-06
Revenue YoY Growth
-2.5%
YoY Comparison
Gross Margin
24.4%
Latest Quarter
Free Cash Flow
$562000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is NOV Overvalued?
Because NOV's trailing net income is positive but negligible (EPS of $0.025, net margin 1.66%), the trailing PE of 40.08x is distorted and not the most informative metric; the forward PE of 15.68x is far more meaningful because it reflects the consensus 2026 EPS estimate of $1.92. The enormous gap between the 40.08x trailing and 15.68x forward multiple implies the market expects a roughly 77-fold earnings recovery, a highly optimistic assumption that leaves little room for execution error. On a sales basis, the PS ratio of 0.66x and EV/Sales of 0.99x are the cleaner valuation anchors for a low-margin capital-goods company. NOV trades at a steep discount to its own history: the PS ratio of 0.66x compares to historical quarterly readings of 2.13x-2.76x in 2025 and 3.0x-4.9x in 2022-2023, and the PB ratio of 0.93x is below the 1.0x-1.6x range seen from 2021 through 2024. Relative to the broader oil & gas equipment & services sector, where peers typically command mid-to-high single-digit EV/EBITDA and 1.5x-3.0x sales multiples, NOV's 8.07x EV/EBITDA and 0.99x EV/Sales present a mixed picture — cheap on sales, but not obviously cheap on EBITDA given its depressed margins. The discount appears partly justified by inferior profitability (2.31% ROE, 6.45% operating margin) and negative GAAP earnings, but the 0.93x price-to-book and 15% FCF yield suggest the market is pricing in substantial skepticism about the durability of cash generation. Historically, NOV's PE has swung wildly (from -18x to 49x) due to cyclical earnings, so the PB and PS bands are more reliable guides; at 0.93x book and 0.66x sales, the stock is near the bottom of its multi-year valuation range, which historically has coincided with cyclical troughs and subsequent recoveries — a value opportunity if the earnings recovery materializes, or a value trap if it does not.
PE
40.1x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 3x~30x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
8.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are elevated by the collapse in GAAP profitability. Q4 2025 swung to a $78 million net loss from $160 million of net income a year earlier, with a $147 million tax expense against only $66 million of pretax income amplifying the damage. Gross margin fell to 20.29% from 21.36%, operating margin is just 6.45%, and ROE of 2.31% is weak for a capital-goods supplier. The dividend payout ratio of 131% means the distribution is not covered by earnings and depends entirely on the $876 million trailing FCF, so any cash-flow deterioration would put the payout at risk. Revenue concentration in oil and gas capital spending, with roughly two-thirds from international markets, means a global drilling slowdown would hit both segments simultaneously.
Market and competitive risks center on valuation compression and cyclical exposure. At 8.07x EV/EBITDA and 0.99x EV/Sales, NOV is cheap on sales but not on EBITDA given its depressed margins, and the 15.68x forward PE already discounts a 77-fold earnings recovery. If that recovery disappoints, the multiple could compress toward the low end of its historical range, and the 0.944 beta offers little downside cushion in a broad market selloff. The wide analyst target range of $17.00 to $26.00 — a $9.00 spread, or roughly 45% of the current price — signals genuine disagreement about the cycle, with Goldman Sachs maintaining a Sell while others are Neutral. Competitive pressure from lower-cost international equipment suppliers and the risk of oil-price weakness curtailing customer capex are persistent overhangs.
In a worst-case scenario, a failure of the international/offshore recovery combined with further North American activity declines would push revenue below the 2025 level, keep GAAP earnings near zero, and force the market to re-rate the stock on cash flow alone. The realistic downside is a move toward the 52-week low of $12.29, which is approximately 39% below the current price of $20.07, or toward the analyst low target of $17.00, about 15% below current. The maximum drawdown of -17.06% over the past period shows the stock can correct sharply even within its uptrend, and a break below the $18.00-$18.50 support zone would likely accelerate selling toward the low end of the range. In this adverse scenario, an investor could lose 15% to 39% from the current price.
FAQ
The most severe risk is earnings risk: Q4 2025 produced a $78 million net loss and trailing EPS of just $0.025, so any failure to hit the $1.92 consensus 2026 EPS would undermine the entire valuation case. Second is margin risk, with gross margin at 20.29% down from 21.36% a year earlier and operating margin at 6.45%, leaving little buffer if pricing pressure persists. Third is dividend sustainability risk, as the 131% payout ratio exceeds GAAP earnings and depends on the $876 million trailing FCF holding up. Fourth is cyclical/macro risk, with a 0.944 beta and roughly two-thirds of revenue from international markets, making the stock sensitive to global drilling capex and oil-price swings. These are ranked from most to least immediate, with the earnings and margin risks being the most likely to trigger a re-rating.
The 12-month forecast has three scenarios. The base case (50% probability) targets $21.00-$23.00, assuming the consensus 2026 EPS of $1.92 and revenue of $10.06 billion are achieved and the stock trades around the $22.24 average analyst target. The bull case (25% probability) targets $24.00-$26.00, driven by an accelerating international/offshore upcycle, gross margin recovery above 21%, and multiple expansion toward the $26.00 high target. The bear case (25% probability) targets $17.00-$18.00, reflecting stalled revenue, continued margin compression, and a re-rating toward the $17.00 low target, with downside risk to the $12.29 52-week low. The base case is most likely, and its key assumption is that revenue returns to growth and EPS recovers toward $1.92.
NOV screens as undervalued relative to its own history but fairly valued relative to current earnings. The PS ratio of 0.66x is far below historical readings of 2.13x-2.76x in 2025 and 3.0x-4.9x in 2022-2023, and the PB ratio of 0.93x is below the 1.0x-1.6x range seen from 2021 through 2024. On EV/EBITDA of 8.07x, however, the stock is not obviously cheap versus peers given its 6.45% operating margin and 2.31% ROE. The 15.68x forward PE implies the market expects a roughly 77-fold earnings recovery from the trailing $0.025 EPS, a highly optimistic assumption. The market is paying a discount on assets and sales but a full price on forward earnings, implying it expects the recovery but is not willing to pay up for uncertainty.
From a risk/reward perspective, NOV is a balanced proposition rather than a clear buy. The average analyst target of $22.24 implies roughly 10.8% upside from $20.07, and the 15.68x forward PE looks reasonable if the consensus 2026 EPS of $1.92 is achieved. However, the trailing PE of 40.08x and the Q4 2025 net loss of $78 million show how far current earnings are from that forecast, and the 131% payout ratio means the dividend is not covered by GAAP earnings. The biggest downside risk is a move toward the analyst low target of $17.00, about 15% below current, or the 52-week low of $12.29, roughly 39% below. It is a good buy for value-oriented investors with a 12-18 month horizon who believe the international/offshore capex recovery will materialize, but not for those seeking near-term earnings visibility or income safety.
NOV is better suited for a medium-to-long-term holding period of at least 12-18 months rather than short-term trading. The stock is in a cyclical recovery phase with negative GAAP earnings and a 131% payout ratio, so the thesis depends on multi-quarter margin and revenue improvement that will not resolve quickly. The 0.944 beta means it is slightly less volatile than the market, and the 3.27% dividend yield provides some carry while waiting, though the payout is not covered by earnings. Short-term traders could exploit the 7.73 short ratio and the $18.00-$21.93 range, but the wide analyst target spread of $17.00-$26.00 and the 17.06% maximum drawdown make short-term positioning risky. A minimum holding period of 12-18 months aligns with the expected timing of the international/offshore capex recovery.